United Therapeutics (NASDAQ:UTHR) Posts Earnings Results, Beats Expectations By $0.92 EPS

United Therapeutics (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92, FiscalAI reports. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the business posted $6.19 EPS. The business’s revenue was up 7.4% on a year-over-year basis.

Here are the key takeaways from United Therapeutics’ conference call:

• United Therapeutics unveiled Tresmi, a soft‑mist treprostinil inhaler that the company says reduced coughing by up to 90% in human studies, with plans to file for PAH and ILD this year and commercially launch next year.
• Management will unblind an outcome study next week for a touted “super prostacyclin” that they say has longer durability and stronger receptor binding, enabling a once‑daily oral treatment they believe could reshape PAH dosing.
• The TETON‑1 pivotal IPF trial will be unblinded next month; management is confident TETON‑2 results will replicate and says it will file and aim to commercialize a superior IPF therapy by June 2027 if confirmed.
• 2025 results were record‑setting (total revenue surpassed $3 billion, +11% YoY; Q4 revenue $790M and Tyvaso $464M, +12% YoY with Tyvaso DPI +24%), and the company reiterates a target to reach a $4 billion annual run rate by end‑2027, while noting quarter‑to‑quarter sales can fluctuate with distributor ordering seasonality.
• Transplant programs progressed — Zeno has two patients transplanted with a 6‑patient cohort expected to complete enrollment by summer (commercial target ~2030), and Miromatrix completed its first manufactured liver trial with FDA guidance expected this year — but these initiatives are multiyear and carry significant regulatory and execution risk.

United Therapeutics Stock Down 0.9%

United Therapeutics stock traded down $4.60 during trading hours on Friday, hitting $499.01. 102,219 shares of the company traded hands, compared to its average volume of 351,577. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $537.19. The firm has a market cap of $21.49 billion, a P/E ratio of 17.88, a P/E/G ratio of 2.85 and a beta of 0.85. The firm’s 50-day simple moving average is $484.64 and its two-hundred day simple moving average is $444.51.

Analysts Set New Price Targets

Several equities research analysts have weighed in on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. TD Cowen upped their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, UBS Group restated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $533.55.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and bullish guidance: UTHR reported $7.70 EPS vs. $6.78 expected, highlighted Tyvaso DPI sales growth and management reiterated growth targets, which prompted a sharp post‑earnings rally. Zacks: UTHR Tops Q4
• Positive Sentiment: Longer‑term revenue target: Management is aiming for roughly a $4B revenue run‑rate by 2027 as late‑stage product launches approach — supports a multi‑quarter growth thesis. Seeking Alpha: $4B target
• Positive Sentiment: Analysts lifting targets: Several firms (H.C. Wainwright, Oppenheimer, RBC) raised price targets and reiterations of Outperform/Buy lifted upside expectations. StreetInsider: PT raises
• Positive Sentiment: Unusually bullish options flow: Large call buying around the print indicates traders positioned for further upside or volatility after earnings. AmericanBankingNews: options volume
• Neutral Sentiment: Relative strength / momentum: UTHR earned a high RS (91) rating, signaling market leadership but not a valuation judgment. MSN: RS rating
• Neutral Sentiment: Mixed analyst stances remain: Some firms (BTIG, Morgan Stanley) stayed on Hold or flagged near‑term franchise headwinds despite pipeline upside, so street views are not unanimous. TipRanks: Hold rationale
• Negative Sentiment: Revenue missed consensus: Q4 revenue of $790.2M came in below the ~$814.8M street estimate, a reminder that top‑line execution could cap multiple expansion. Yahoo Finance: Why shares are sliding
• Negative Sentiment: Insider selling: The COO disclosed a multi‑million dollar sale (~$6.8M) and a director sold shares in February — multiple insider disposals can raise investor concern about near‑term conviction. AmericanBankingNews: COO sale InsiderTrades: director sale

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 21,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the transaction, the chief financial officer owned 8,142 shares in the company, valued at $3,908,078.58. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00. The disclosure for this sale is available in the SEC filing. Insiders sold 407,954 shares of company stock valued at $197,601,528 over the last quarter. Insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. Finally, State of Wyoming acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $55,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.